Search

Type 2 diabetes mellitus (DM) has a detrimental impact on cardiovascular outcomes, with implications for prognosis following ST elevation myocardial infarction (STEMI).The aim was to evaluate the impact of DM and myocardial perfusion on the long-term risk of heart failure (HF) and/or all-cause mortality following primary percutaneous coronary intervention (pPCI) for STEMI. A total of 406 STEMI patients (104 with DM) treated with pPCI were enrolled in this observational study. Myocardial perfusion was reassessed with the Quantitative Myocardial Blush Evaluator. Follow-up data on HF (ICD10 [International Statistical Classification of Diseases] codes I50.0 - I50.9) and all-cause mortality were obtained from the National Health Fund. During a 6-year follow-up, 36 (35%) patients with DM died compared with 45 (15%) patients without DM (p0.001). Also, 24 (23%) patients with DM developed HF compared with 51 (17%) patients without DM (p = 0.20). Patients with DM and HF had the highest mortality rate (75%), and those with DM and a QuBE score below the median value (9.0 arb. units) had significantly higher risk of HF (hazard ratio [HR] =1.96, 95% CI 1.18 to 3.27, p = 0.0099) and the composite of HF and/or all-cause mortality (HR = 1.89, 95% CI 1.33 to 2.69, p = 0.0004). In conclusion DM (type 2) and diminished myocardial perfusion increase the risk of HF and/or all-cause mortality during a 6-year follow-up after pPCI for STEMI.

Introduction Permanent right ventricle pacing leads to left ventricle dyssynchrony, systolic dysfunction, remodeling, and symptomatic heart failure in the long run. Valsartan is well known for its preventive anti-remodeling function in the post infarction heart remodeling. Objectives To assess the effect of valsartan on left ventricle contractility, measured as global longitudinal stain, and its remodeling in patients with second and third degree atrioventricular block with first-time implantation of dual chamber pacemaker. Methods This was a randomized, double-blind, placebo controlled single center study. One hundred eligible patients were assigned in a 1:1:1 fashion to receive placebo, valsartan 80mg or 160mg once daily, respectively. Echocardiographic assessment of left ventricle geometry, its systolic and diastolic function was performed at baseline and at twelve months. Global longitudinal strain (GLS) was measured off-line with EchoPac software. One patient from placebo group suffered stroke. We present the baseline date for 100 enrolled patients and follow-up data for 88 patients who have completed the study. Data in valsartan arms are pooled in one group. Results Results are presented in table. Data are presented as mean and standard deviation. Valsartan alleviates diastolic dysfunction, left ventricle dilation and protects from loss of systolic function. Conclusion Valsartan has protective effect of left ventricle contractile function and remodeling. It may be useful in prevention of pacing induced heart failure. (ClinicalTrials Identifier NCT01805804) Funding Acknowledgement Type of funding source: Public grant(s) – National budget only. Main funding source(s): Medical University of Silesia

Patients with type 2 diabetes mellitus (T2DM) who undergo primary percutaneous coronary intervention (pPCI) for ST-elevation myocardial infarction (STEMI) have worse myocardial perfusion than normoglycemic patients. It is not known whether these factors combined influence prognosis in term of heart failure (HF) and/or all-cause mortality. We aimed to evaluate the impact of T2DM and myocardial perfusion on long-term risk of HF and/or all-cause mortality following interventional treatment of STEMI. 4STEMI patients (104 with T2DM) treated with pPCI were enrolled into the study. Myocardial perfusion was reassessed with: myocardial blush grade (MBG), Quantitative myocardial Blush Evaluator (QuBE), resolution of ST-segment elevation (STR). Follow-up data was collected during 6 years. 23.1% patients with T2DM developed HF vs. 16.9% without T2DM (P=NS). 34.6% of patients with T2DM have died vs. 14.9% patients without T2DM (P=0.000). Patients with T2DM and HF have had the highest mortality rate of 75%. Survival of patients with T2DM in relation to QuBe score is presented in the Figure. There was no difference in myocardial perfusion assessed by STR. T2DM and diminished myocardial perfusion increase the risk of HF and/or all cause death in 6 years follow-up. Disclosure A. Tomasik: None. K. Nabrdalik: None. H. Kwiendacz: None. T. Sawczyn: None. M. Kukla: None. E. Radzik: None. K. Pigon: None. T. Młyńczak: None. J. Gumprecht: Speaker's Bureau; Self; AstraZeneca. Consultant; Self; Bayer AG. Speaker's Bureau; Self; Bioton, Berlin-Chemie AG, Eli Lilly and Company, Merck Sharp & Dohme Corp., Boehringer Ingelheim GmbH, Novo Nordisk A/S, Polfa Tarchomin S.A., Polpharma. W. Grzeszczak: Speaker's Bureau; Self; Boehringer Ingelheim GmbH, Bioton, Merck & Co., Inc., Novo Nordisk A/S. Stock/Shareholder; Self; Eli Lilly and Company. Speaker's Bureau; Self; Bayer AG. E. Nowalany-Kozielska: None.

Aim: Study was aimed to assess the real-world costs of manual thrombectomy (MT) in selected ST-segment elevation myocardial infarction patients with intracoronary thrombus (IT). Methods: Study group (IT+) comprised 51 patients with MT applied and control group (IT-) comprised 56 patients without IT who underwent angioplasty alone. Costs comprised hospital care and cost of disposable materials used during primary angioplasty. Results: Complex management of patients with IT is more expensive, though allows to achieve clinical outcomes comparable to low-risk ST-segment elevation myocardial infarction patients without IT. Conclusion: A complex pharmaco-interventional strategy, with glycoprotein IIB/IIIA inhibitor and MT, though more expensive, may prove cost-effective.

Background: Acute myocardial infarction (AMI) might lead to left ventricular remodeling. Adequate myocardial perfusion is critical to prevent this adverse remodeling. Quantitative myocardial blush evaluator (QuBE) software, available on-line, is a simple analysis tool which enables the precise quan­tification of myocardial perfusion in the infarct area immediately after interventional treatment. The aim of this study was to assess whether the results of QuBE analysis might predict the development of heart failure (HF) in AMI patients in 3 year-long follow-up. Methods: Ninety five patients with first AMI, single vessel coronary artery disease, Killip class I at presentation were enrolled in the study. Angiograms were reanalyzed using the on-line QuBE software. Data on heart failure development (ICD 10 codes I50) provided by the National Health Fund were considered as primary outcome. Results: QuBE values ranged from 0.0 to 25.3 arbitrary units, mean value was 9.9 ± 5.2 arbitrary units. QuBE correlated positively with myocardial blush grade (MBG; Spearman R = 0.342 at p < 0.05). Multivariate Cox proportional hazard modeling, adjusted for initial Thrombolysis in Myocardial In­farction (TIMI flow, and TIMI thrombus grade indicated QuBE score (1 unit increase — HR 0.919, 95% CI 0.846–0.999, p = 0.049) and left ventricular ejection fraction at discharge (1% increase — HR 0.936, 95% CI 0.902–0.971, p = 0.000) as independent predictors of HF development. Conclusions: The QuBE assessment of myocardial perfusion allows the prediction of HF development in the post-infarction period in this highly selective group of patients.